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The repertoire of human cytotoxic T-lymphocytes (CTL) in response to influenza A viruses has been shown
to be directed towards multiple epitopes, with a dominant response to the HLA-A2-restricted M158–66 epitope.
These studies, however, were performed with peripheral blood mononuclear cells (PBMC) of individuals
selected randomly with respect to HLA phenotype or selected for the expression of one HLA allele without
considering an influence of other HLA molecules. In addition, little information is available on the influence
of HLA makeup on the overall CTL response against influenza viruses. Here, the influenza A virus-specific CTL
response was investigated in groups of HLA-A and -B identical individuals. Between groups the individuals
shared two or three of the four HLA-A and -B alleles. After in vitro stimulation of PBMC with influenza virus,
the highest CTL activity was found in HLA-A2 donors. A similar pattern was observed for the precursor
frequency of virus-specific CTL (CTLp) ex vivo, with a higher CTLp frequency in HLA-A2-positive donors than
in HLA-A2-negative donors, which were unable to recognize the immunodominant M158–66 epitope. In addition,
CTL activity and frequency of CTLp for the individual influenza virus epitopes were determined. The frequency
of CTLp specific for the HLA-B8-restricted epitope NP380–388 was threefold lower in HLA-B27-positive donors
than in HLA-B27-negative donors. In addition, the frequency of CTLp specific for the HLA-A1-restricted
epitope NP44–52 was threefold higher in HLA-A1-, -A2-, -B8-, and -B35-positive donors than in other donors,
which was confirmed by measuring the CTL activity in vitro. These findings indicate that the epitope specificity
of the CTL response is related to the phenotype of the other HLA molecules. Furthermore, the magnitude of
the influenza virus-specific CTL response seems dependent on the HLA-A and -B phenotypes.
Influenza viruses are negative-sense RNA viruses that cause
annual epidemics in the human population. Vaccination
against influenza virus, aiming at the induction of virus neu-
tralizing antibodies specific for the hemagglutinin (HA) and
neuraminidase (NA) proteins, induces protective immunity
when the HA and NA proteins of the vaccine strains closely
resemble those of the circulating virus strains. Mutation of
these proteins can result in viral escape from neutralizing an-
tibodies (antigenic drift). In addition, occasionally new poten-
tially pandemic influenza viruses emerge with novel HA and
NA proteins, against which preexisting antibodies are absent in
the human population (antigenic shift). In these cases, cyto-
toxic T lymphocytes (CTL) directed to more conserved inter-
nal proteins, such as nucleoprotein (NP), matrix protein, and
polymerase proteins may contribute to protective immunity
against these pandemic viruses (25, 32, 37, 49), although
changes in these internal proteins causing loss of CTL recog-
nition have also been described (33, 51).
Influenza virus-specific CTL-mediated immunity has been
investigated in both humans and mice. In mice, the CTL re-
sponse was found to be directed to a limited number of
epitopes. This ability of the immune system to focus the T-cell
responses to a limited number of epitopes is termed immu-
nodominance (7, 8, 25, 52). In B6 mice the influenza A virus-
specific CTL responses were directed against a number of
H-2b-restricted immunodominant epitopes (3, 5, 6). Likewise,
after an infection of lymphocytic choriomeningitis virus, the
CTL response in mice was mainly directed against an epitope
derived from the NP (50). Similar examples of immunodomi-
nance have been described for humans. In HLA-A2 donors,
the CTL response against influenza virus is predominantly
directed to the HLA-A2-restricted epitope of the matrix pro-
tein (GILGFVFTL; M158–66) (2, 24, 25, 39). For Epstein-Barr
virus (EBV) infections it was reported that the cellular re-
sponse is focused towards HLA-A11- and HLA-B8-restricted
epitopes (23, 46). Nevertheless, other studies have indicated
that the CTL response after both acute (influenza virus) and
chronic (human immunodeficiency virus [HIV]) viral infec-
tions can be directed to a large number of epitopes (9, 28, 45).
Several factors have been reported to contribute to the phe-
nomenon of immunodominance, such as gamma interferon
(IFN-) production, major histocompatibility complex (MHC)
binding affinity of the epitopes, available T-cell receptor rep-
ertoire, epitope abundance, and antigen processing (1, 12, 13,
16, 21, 22, 38). However, the correlation between immu-
nodominance and epitope-MHC binding affinity is presently
under debate (15, 40). Several other factors that could possibly
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have an effect on immunodominance have not been investi-
gated thoroughly, such as the influence of HLA phenotype and
patient age, gender, and history of infection. The first evidence
regarding the involvement of MHC phenotype in immu-
nodominance was observed by Doherty et al., describing in
mice a minimization of the H-2Db response in the presence of
H-2Kk (18). Using modern tools for the measurement of CTL
activity, these early findings were confirmed recently (4). In
humans the role of HLA phenotype in immunodominance is
still unclear. Tussey et al. described the absence of an HLA-
B8-restricted response against the influenza A virus NP380–388
epitope in a HLA-B27, HLA-B8 donor (48) due to compe-
tition for overlapping epitopes in the endoplasmatic reticulum
by HLA-B8 and HLA-B*2702, resulting in the suboptimal
loading of HLA-B8.
Although influenza virus-specific immunity mediated by
CTL has been studied to a certain extent, in these studies
peripheral blood mononuclear cells (PBMC) were obtained
from donors selected for the presence of one particular HLA
molecule, not controlling for HLA background, age, or history
of infection. In the present study CTL immunity to influenza A
virus and its individual epitopes was studied in donors with
identical HLA-A and -B phenotypes and was compared with
that of donors who share two or three out of the four HLA-A
or -B alleles, enabling us to investigate the effect of HLA
phenotype on the specificity and the magnitude of the CTL
response. To this end the precursor frequency of CTL (CTLp)
and CTL activity directed against influenza A virus and indi-
vidual epitopes were determined ex vivo and after in vitro
stimulation of PBMC with influenza virus, respectively.
MATERIALS AND METHODS
Human subjects. A total of 18 healthy blood donors, between 35 and 50 years
of age, were selected according to serological homology within the A locus and
B locus of HLA class I molecules (Table 1). Genetic subtyping of the HLA-A and
HLA-B loci was performed by using a commercial typing system (GenoVision,
Vienna, Austria). PBMC were isolated by Lymphoprep (Nycomed, Norway)
gradient centrifugation and were cryopreserved at 135°C. Serum samples were
stored at 20°C and were used for serology (see below). All donors had serum
antibodies against one or more influenza A virus strains (A/H1N1 or A/H3N2),
measured by hemagglutination inhibition assay (HIA), indicative of one or more
exposures to influenza virus in the past.
Serology. Serum samples were tested for the presence of influenza A virus-
specific antibodies in the HIA according to standard methods (36, 41) using
turkey erythrocytes. The sera were tested for antibodies against 10 influenza virus
(A/H3N2) vaccine strains used since the emergence of these viruses in 1968 and
for antibodies against 9 A/H1N1 strains, including the first isolate of H1N1
(A/Puerto Rico/8/34) and the latest H1N1 vaccine strain (A/New Caledonia/20/
99). Ferret sera raised against the test antigens were used as positive controls.
Preparation of BLCL. Autologous EBV-transformed B-lymphoblastoid cell
lines (BLCL) of each donor was established by culturing 1  106 to 5  106
PBMC in 1 ml of culture supernatant from the EBV-producing cell line S594 in
24-well plates as previously described (43). No BLCL were established for donors
11 and 13
Influenza virus and peptides. Sucrose gradient-purified influenza A virus
(H3N2) Resvir-9, a reassortant between A/Puerto Rico/8/34 (H1N1) and A/Nan-
chang/933/95 (H3N2), was used for the infection of PBMC or BLCL. The virus
was selected for this study because it contains all known influenza A virus CTL
epitopes, in contrast to other virus strains (51). The infectious virus titer (109
50% tissue culture infectious doses) was determined in cell culture using Madin-
Darby-Canine-Kidney (MDCK) cells as indicator cells, as described previously
(42). All peptides (Table 2) corresponding to influenza A virus CTL epitopes
were manufactured, high-performance liquid chromatography purified, and an-
alyzed by mass spectrometry (Eurogentec, Seraing, Belgium). Peptides were
dissolved in dimethyl sulfoxide at 5.0 g/ml, diluted in RPMI 1640 (Life Tech-
nologies, Rockville, Md.) to 100 M, and stored at 20°C.
Infected PBMC for the stimulation of influenza virus-specific CTL. In order to
validate the antigen-presenting capacity of PBMC, cells (106/ml) from two HLA-
A2-negative, HLA-A1-positive donors were infected with influenza virus (Resvir-9)
at a multiplicity of infection (MOI) of 3 in RPMI 1640 supplemented with 10%
fetal calf serum, glutamin (2 mM), streptomycin (100 g/ml), and penicillin (100
IU/ml) (R10F). After 1 h of incubation at 37°C, the cells were pelleted and
resuspended in RPMI 1640 medium supplemented with 10% pooled human AB
serum, glutamin (2 mM), streptomycin (100 g/ml), penicillin (100 IU/ml), and
2-mercaptoethanol (20 M) (R10H) at a concentration of 2  106 cells/ml and
distributed in a 96-well U-bottom plate (100 l). In duplicate wells various
numbers of cells of an HLA-A2, HLA-A1-restricted T-cell clone (A1/NP),
specific for the influenza A virus NP44–52 epitope, were added and incubated for
5 h at 37°C. Next, GolgiStop (Pharmingen, San Diego, Calif.) was added to each
well and the cells were incubated for a subsequent 6 h at 37°C. The staining of
intracellular IFN- was performed as recommended by the manufacturer by
using a Cytofix/Cytoperm kit (Pharmingen), phycoerythrin-conjugated anti-
IFN- monoclonal antibody (MAb) (559326; Pharmingen), mouse anti-human-
HLA-A2 MAb (Biotest AG, Dreieich, Germany), and a fluorescein isothiocya-
nate (FITC)-conjugated rabbit anti-mouse MAb (F0313; Dako, Glostup,
Denmark) at previously determined optimal MAb concentrations. The percent-
age of HLA-A2, IFN- cells of the A1/NP clone was determined by flow
cytometry. A1/NP stimulated with peptide-loaded BLCL and uninfected PBMC




I 1 0101, 0201 0801, 3501
2 0101, 0201 0801, 3501
3 0101, 0201 0801, 3501
4 0101, 0201 0801, 3501
II 5 0101, 0201 0801, 2705
6 0101, 0201 0801, 2705
7 0101, 0201 0801, 2705
8 0101, 0201 0801, 2702
9 0101, 0201 0801, 2705
III 10 0101, 0301 0801, 3501
11 0101, 0301 0801, 3501
12 0101, 0301 0801, 3501
13 0101, 0301 0801, 3501
14 0101, 0301 0801, 3501
15 0101, 0301 0801, 3503
16 0101, 0301 0801, 3503
IV 17 0201, 0302 2705, 3501
V 18 0201, 0301 0801, 3501
TABLE 2. Influenza virus CTL epitopes used in this study
Epitope Antigen(amino acid positions)
Restriction
element Reference
CTELKLSDY NP (44–52) HLA-A1 17
VSDGGPNLY PB1 (591–599) HLA-A1 17
GILGFVFTL M1 (58–66) HLA-A*0201 2, 39
AIMDKNIIL NS1 (122–130) HLA-A*0201 33
ILRGSVAHK NP (265–273) HLA-A3 17
ELRSRYWAI NP (380–388) HLA-B*0801 47
ADRGLLRDIa NP (263–271) HLA-B8 44
SRYWAIRTR NP (383–391) HLA-B*2705 48, 27
RRSGAAGAAVK NP (174–184) HLA-B27 29
ASCMGLIY M1 (128–135) HLA-B*3501 19
a Influenza B virus epitope.
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were included as positive and negative controls, respectively. The assay was done
in duplicate and the results were calculated from the averages of duplicate wells.
In vitro stimulation of PBMC with influenza virus. PBMC were resuspended
at 106/ml in R10F and infected with influenza A virus (Resvir-9) at an MOI of 3
for 1 h at 37°C. After centrifugation the stimulator PBMC were resuspended in
R10H and added to uninfected responder PBMC in a 25-cm2-diameter flask at
a ratio of 1:1, which was found to be optimal. A total of 10  106 PBMC were
incubated for 2 days at 37°C before recombinant interleukin 2 was added (50
U/ml). Following a subsequent 7-day incubation at 37°C the cells were harvested,
analyzed by flow cytometry, and used as effector cells in the CTL assay.
CTL assay. HLA-A- and HLA-B-matched BLCL (106) were incubated in
R10F in the presence of 5 M peptide (Table 2) and were used as target cells.
In addition, BLCL were infected with influenza A virus (Resvir-9) at an MOI of
1 or were left untreated and used as positive and negative controls, respectively.
In order to rule out any bystander activation, every CTL assay contained target
cells loaded with an HLA-B8-restricted influenza B virus epitope (NP263–271;
Table 2). After incubation for 16 h at 37°C, target cells were washed once in
serum-free medium and 5  105 target cells were labeled for 1 h at 37°C with 50
Ci of Na2[51Cr]O4 in RPMI 1640 medium. The cells were washed three times
in R10F and resuspended at 105 cells/ml. Effector cells were transferred to
96-well V-bottom plates at a concentration of 1  105 and 5  104 cells/100 l,
and 50 l of the different target cells were added (effector:target cell ratio [E:T
ratio] of 20:1 and 10:1). Furthermore, target cells were lysed with 100 l of 10%
Triton X-100 or incubated with R10F to determine the maximum and sponta-
neous release. Following 4 h of incubation at 37°C, the supernatants were
harvested (Skatron Instruments, Sterling, Va.) and radioactivity was measured by
gamma counting. The percentage of specific lysis was calculated with the follow-
ing formula: [(experimental release  spontaneous release)/(maximum re-
lease  spontaneous release)]  100. The data are presented as the average
specific lysis of at least three wells.
Detection of CTL specific for individual influenza virus epitopes by ELISPOT
assay. A 96-well Silent Screen Plate (Life Technologies) was coated with 7.5 g
of anti-IFN- MAb 1-DIK (Mabtech, Stockholm, Sweden)/ml in 100 l of sodi-
um-bicarbonate buffer (0.1 M) overnight at 4°C. The plates were washed three
times with phosphate-buffered saline (PBS) and blocked with R10H for 2 h at
37°C. For the detection of epitope-specific CD8 T cells, PBMC were incubated
at a density of 2.5  105 cells/well in 150 l of R10H in the presence of
HLA-compatible peptides (10 M) in quadruplicate wells. The specificity of the
ELISPOT assay for the enumeration of epitope-specific CD8 T cells was pre-
viously validated by others (31). Cells treated with phytohemagglutinin (1 g/ml)
(Roche Diagnostics, Mannheim, Germany) and untreated cells were used as
positive and negative controls, respectively. After 6 h at 37°C the wells were
washed six times with PBS–0.05% Tween 20 (PBST) (Sigma Chemical Co., St.
Louis, Mo.). Detection of secreted IFN- was done with 100 l of biotinylated
anti-IFN- MAb 7-B6-1 (1.0 g/ml; Mabtech) overnight at 4°C. After the plates
were washed three times with PBST, 100 l of a 1:1,000 diluted streptavidin
labeled with alkalin phosphatase was added for 1 h at room temperature. The
plates were subsequently washed three times and 100 l of a phosphatase
substrate, BCIP/NBT (Kirkegaard & Perry Laboratories, Gaithersburg, Md.),
was added per well. After an incubation of 1 h at room temperature the reaction
was terminated by washing the plates three times with water. The frequency of
peptide-specific CTLp was based on the number of spots obtained in two inde-
pendent experiments, counted by two individuals, and given as the number of
CTLp per 2.5  105 PBMC for peptide-specific cells or percentage of CTLp
within the CD8 T-cell fraction.
Detection of virus-specific CTL by ELISPOT assay. Since it has been shown
that NK cells are specifically activated by influenza virus-infected cells (34), it was
necessary to isolate the CD8 T lymphocytes, followed by the depletion of
CD16 cells, using Dynabeads (see below) in order to exclude IFN- spots
produced by CD4 T cells or NK cells. The CD3, CD8, CD16-negative cells
(98% pure) were incubated with 4  104 autologous influenza A virus-infected
BLCL or uninfected BLCL for 90 min at 37°C in a 96-well V-bottom plate
following centrifugation for 1 min at 140 g. For donor 11 and 13 no autologous
BLCL were available, and therefore HLA-A- and HLA–B-matched BLCL from
donor 10 were used. A total number of 2 104 or 1 104 effector cells was used,
and the assay was performed in quadruplicate. After preincubation the cells were
transferred to a plate coated with anti-IFN- MAb 1-DIK (see above) and
incubated for an additional 5 h at 37°C. Virus-specific CD8 T cells were
visualized as described above, and the spots were counted by two individuals. The
frequency of virus-specific CTLp was calculated from the number of specific
spots of multiple experiments and given as the percentage of influenza A virus-
specific CD8 T cells within the total CD8 population.
Characterization, depletion, and isolation of T cells from PBMC. Depletion
and isolation of CD4 or CD8 T cells was performed using DYNABEADS
M-450 (111.05 and 111.07; Dynal, Oslo, Norway) according to the manufactur-
er’s protocol. The depletion of CD16 cells was done with pan-anti-mouse
immunoglobulin G-labeled Dynabeads (110.22; Dynal) coupled to mouse anti-
human-CD16 MAb (30621A; Pharmingen). The success of the procedure was
monitored by flow cytometry, using mouse MAb against human CD3 (CD3-RPE;
Dako), CD4 (CD4-RPE; Dako), CD8 (CD8-FITC; Dako) and CD16 (CD16;
Dako). Flow cytometry was also used to determine the percentage of CD3,
CD4, and CD8 cells in each donor before and after stimulation of PBMC with
influenza virus.
Statistical analysis. Results are presented as means  standard deviations
(SD). Statistical significance was determined by using a Student’s t test, and a P
value of 0.05 was considered statistically significant. Donors with a genotypic
mismatch for a certain HLA class I allele were excluded from the data analysis.
RESULTS
Infected PBMC as antigen-presenting cells for the stimula-
tion of influenza virus-specific CTL. Using an HLA-A1-re-
stricted T-cell clone (A1/NP) specific for NP44–52, the antigen-
presenting capacity of influenza virus-infected PBMC was
evaluated. First it was demonstrated that a maximum of 58.1%
of the cells of the A1/NP clone were activated after stimulation
with peptide-loaded HLA-A1 BLCL. This percentage was
used to calculate the expected percentage of IFN--producing
cells of the A1/NP clone after stimulation with virus-infected
HLA-A1 PBMC (Fig. 1, dotted line), which was compared
with the percentage of cells that were actually activated (Fig. 1,
solid circle). Influenza virus-infected PBMC of donor A acti-
vated cells of the A1/NP clone to a similar extent as peptide-
loaded BLCL when the A1/NP cells constituted up to 4% of
the PBMC population (Fig. 1A). At higher cell numbers of the
A1/NP clone the antigen-presenting capacity of infected
PBMC was no longer sufficient for the activation of all A1/NP
cells. Influenza virus-infected PBMC of donor B activated the
A1/NP cells when they constituted up to 2% of the total PBMC
population (Fig. 1B).
CD8 phenotype of effector cells in CTL assays. To assess
whether in vitro-expanded CD8 T cells were responsible for
the lysis of influenza A virus-infected or peptide-loaded target
cells, PBMC of one donor were stimulated with influenza virus,
followed by a CTL assay against HLA-matched target cells
infected with influenza virus or loaded with a number of dif-
ferent peptides. Prior to the CTL assay the effector cells were
divided into three portions. One portion was used to deplete
CD4 T cells, from a second portion the CD8 T cells were
depleted, and a third portion was used as unseparated control
cells. The depletion of either CD4 or CD8 T cells was
confirmed by flow cytometry (Fig. 2). The three effector cell
populations were added to target cells at an E:T ratio of 10:1.
The lysis of virus-infected target cells and peptide-loaded tar-
get cells increased after depletion of CD4 T cells compared
to that of the unseparated control effector cell population.
However, after depletion of CD8 T cells it was found that the
specific lysis of the target cells was reduced to background
levels (Fig. 2), indicating that the CD8 T cells were respon-
sible for the lytic activity of virus-stimulated bulk cultures.
CTL responses to influenza virus and epitopes in HLA class
I defined donors. The CTL responses specific for influenza A
virus or viral epitopes were compared within a group of
HLA-A and -B identical donors or between groups of donors
mismatched for one HLA molecule. The percentage of specific
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lysis for HLA-A1-, HLA-A2-, HLA-B8-, HLA-B35-positive
donors revealed two donors (donors 1 and 2) with the highest
percentages of specific lysis against target cells loaded with the
HLA-A2-restricted M158–66 epitope (Fig. 3, group I). In donor
3 the highest response was directed towards NP44–52 (HLA-
A1), while donor 4 demonstrated the highest response towards
NS1122–130, a second HLA-A2-restricted epitope. In the sec-
ond group, containing HLA-A1-, HLA-A2-, HLA-B8-, HLA-
B27-positive donors, the response was dominated by the
M158–66 epitope in four out of five donors (Fig. 3, group II).
One donor (donor 6) showed a greater response against the
HLA-B27-restricted NP383–391 epitope. HLA-A1-, HLA-A3-,
HLA-B8-, HLA-B35-positive donors within group III (Table
1) demonstrated a more diverse response against the different
epitopes tested. From the seven donors within group III, three
donors showed the highest response to the HLA-B8-restricted
epitope NP380–388 (Fig. 3, group III). Furthermore, donor 14
had the highest response to the HLA-A3-restricted epitope
NP265–273, donor 10 had the highest response against the HLA-
B35-restricted epitope M1128–135, and finally donors 11 and 12
responded best to the HLA-A1-restricted epitope PB1591–599.
Of the remaining two donors, donor 17, an HLA-A2-, HLA-
A3-, HLA-B8-, HLA-B27-positive donor, had the highest per-
centage of specific lysis against the HLA-B27-restricted
epitope NP174–184, whereas donor 18, an HLA-A2-, HLA-A3-,
HLA-B27-, HLA-B35-positive donor, showed the highest re-
sponse to the NP380–388 epitope (data not shown). Overall, the
M158–66-specific response was found to be dominant in 7 out of
11 HLA-A2-positive donors compared with the response
against the other epitopes.
For HLA-A1, -A2, and -B27 the response to multiple pep-
tides presented by one HLA molecule could be investigated. It
was found that for HLA-A2 the response against M158–66 was
higher than the response to NS1122–130 in 10 out of 11 cases
(Fig. 3). For the HLA-B27-restricted epitopes (donor 8 was
excluded due to its HLA-B*2702 genotype), three donors dem-
onstrated the highest response to NP383–391 and two donors to
NP174–184. Finally, the preferred recognition of the two HLA-
A1-restricted epitopes, NP44–52 and PB1591–599, was evenly dis-
tributed over the donors.
FIG. 1. Ability of influenza virus-infected PBMC to activate an
influenza virus-specific CTL clone. Influenza virus-infected (Resvir-9,
MOI 	 3) PBMC or uninfected PBMC from two HLA-A1-positive,
HLA-A2-negative donors (A and B) were incubated in the presence of
serially diluted HLA-A2 A1/NP clone. The percentage of IFN--
positive cells within the A1/NP population was determined by flow
cytometry by using HLA-A2-specific antibodies (). The calculated
percentage of IFN--producing cells of A1/NP clone, determined after
multiplying the maximal percentage of IFN--positive A1/NP cells
after stimulation with NP44–52 (5 M)-loaded HLA-A1-positive, HLA-
A2-negative BLCL (58.1%) with the percentage of cells of the A1/NP
clone present within the total PBMC population, was plotted (dotted
lines). When the experimental value (percentage of IFN--positive
cells) is similar to the calculated value, the virus-infected PBMC are
able to stimulate the cells of the A1/NP clone. Uninfected PBMC did
not induce IFN- production at any percentage of cells of the A1/NP
clone (F). The results represent the averages of duplicate wells.
FIG. 2. CD8 T cells mediate CTL activity of PBMC after in vitro
stimulation with influenza virus. Uninfected PBMC (donor 7) were
stimulated in vitro with influenza virus-infected PBMC (Resvir-9,
MOI	 3) at a ratio of 1:1, and virus-specific T cells were expanded for
9 days. Subsequently the effector cells were divided into three portions:
CD4 depleted (panel C and open bars in panel D), CD8 depleted
(panel B and grey bars in panel D), or unseparated (panel A and black
bars in panel D). Confirmation of depletion was done by flow cytom-
etry (99% pure). The effector cells were added to Na2[
51Cr]O4-
labeled target cells (BLCL) at an E:T ratio of 10:1. BLCL were in-
fected with influenza A virus (Resvir-9, MOI 	 1), left uninfected, or
pulsed with 5 M HLA-matched viral peptide (as indicated). Results
are given as the averages of triplicate wells  SD.
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Comparison of the magnitude of the CTL response against
virus-infected target cells between the groups of donors re-
vealed a lower average percentage of specific lysis of target
cells in group III (P  0.001; Fig. 3). This inferior recognition
of target cells was not caused by a difference in infectibility of
the three target cells (data not shown). Therefore, the lower
percentage of specific lysis observed for donors within group
III is likely to be caused by a reduction in the number of
influenza virus-specific CTL after in vitro stimulation of PBMC
or a reduced lytic capacity of the respective CTL. When the
magnitude of the response against the different influenza virus
epitopes presented by shared HLA molecules (A1, B8) was
compared between the three donor groups, no difference was
found for the HLA-A1-restricted epitope PB1591–599 (Fig. 3).
The second HLA-A1-restricted epitope, NP44–52, had a higher
response in group I than in both groups II and III. The average
percentage of specific lysis specific for the HLA-B8-restricted
NP380–388 epitope was lower in the donors from group II
(HLA-B27) than in the donors from groups I and III. The
response against the only known B35 epitope was very low, and
only two donors (10 and 13) showed a response (5% specific
lysis) against the M1128–135 epitope. As expected, none of the
donors had a response against the HLA-B8-restricted irrele-
vant influenza B virus epitope NP263–271 after stimulation with
influenza A virus (Resvir-9).
Frequencies of T cells specific for individual influenza virus
epitopes in HLA-defined donors. The highest CTLp frequency
in donors 1 and 2 was found to be specific for M158–66 (ranging
from 24.6 to 57 per 2.5  105 PBMC, respectively) as deter-
mined by ELISPOT assay. Donor 3 had the highest frequency
of CTLp specific for NP44–52 (31 per 2.5  10
5 PBMC), and
donor 4 had the highest frequency of CTLp specific for
NS1122–130 (23 per 2.5  10
5 PBMC) (Fig. 4). In donors of
group II a dominance of the M158–66 epitope was found in four
out of five donors, ranging from 15 spots per 2.5  105 PBMC
in donor 9 to 43 spots per 2.5  105 PBMC in donor 5. Donor
6 showed a higher frequency of NP383–391-specific CTL (32 per
2.5  105 PBMC). Five out of seven donors from group III
showed a dominant response to the HLA-B8-restricted
epitope NP380–388 (2 to 26 per 2.5  10
5 PBMC), while the
remaining two donors showed the highest responses to the
PB1591–599 epitope (13 spots per 2.5  10
5 PBMC in donor 11)
and the NP265–273 epitope (12 spots per 2.5  10
5 PBMC in
donor 12), respectively. In donor 17 the dominant response
was directed to NP174–184 (88 spots per 2.5  10
5 PBMC),
while donor 18 had the highest number of spots after stimula-
tion with M158–66 (13 spots per 2.5  10
5 PBMC) (data not
shown).
Comparison of the frequencies of CTLp specific for two
epitopes presented by the same HLA class I molecule showed
that the HLA-A2-restricted epitope M158–66 dominated over
NS1122–130 in 10 out of 11 donors (Fig. 4). Within HLA-B27, a
higher CTLp frequency was found specific for NP383–391 than
for NP174–184 in three out of five donors (Fig. 4 and data not
shown). Finally, for the HLA-A1 molecule the NP44–52 epitope
was dominantly recognized in 8 out of 16 donors and the
PB1591–599 epitope in 4 donors, and the remaining 4 donors
had a similar response to both epitopes or no response at all
(donor 9).
When the CTLp frequency against the different epitopes
was compared between the three groups, a threefold lower
NP380–388-specific CTLp frequency was found for the HLA-
B8, HLA-B27 donors (P	 0.09, group II) compared to that
of HLA-B8-positive, HLA-B27-negative donors (Fig. 4). Fur-
thermore, the NP44–52-specific CTLp frequency in donors from
group I was three times higher than the CTLp frequency in
FIG. 3. Influenza virus- and epitope-specific CTL activity in PBMC
from donors with identical HLA-A and -B phenotypes. PBMC were
stimulated with influenza virus, and the resulting effector cells were
tested for CTL activity against radioactively labeled HLA-A- and
HLA-B-matched target cells (BLCL), either infected with influenza
virus (Resvir-9, MOI 	 1), left uninfected, or loaded with 5 M
peptide (as indicated) at an E:T ratio of 20:1. The three groups cor-
respond to HLA-A1-, HLA-A2-, HLA-B8-, HLA-B35-positive donors
(group I); HLA-A1-, HLA-A2-, HLA-B8-, HLA-B27-positive donors
(group II); and HLA-A1-, HLA-A3-, HLA-B8-, HLA-B35-positive
donors (group III). The percentage of specific lysis was calculated from
at least three wells, and the average CTL activity for a given target cell
within a group is plotted (dotted line). The CTL activity against virus-
infected BLCL and HLA-B27 peptide-pulsed BLCL were not included
for donor 8 (HLA-B*2702). Furthermore, donors 15 and 16 (HLA-
B*3503) were excluded from the calculation of CTL activity specific
for virus-infected BLCL and HLA-B*3501-restricted epitope M1128–135-
pulsed BLCL.
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donors from groups II and III (P 	 0.013). No difference in
the CTLp frequency specific for M158–66, PB1591–599, and
NS1122–130 was observed between the different groups. Finally,
it was noted that the response to the HLA-B35-restricted
epitope M1128–135 was virtually absent in all donors.
Frequencies of influenza virus-specific T cells in HLA-de-
fined donors. The sum of frequencies of CTLp specific for
synthetic peptides representing known CTL epitopes was lower
in HLA-A2-negative donors (group III) than in HLA-A2
donors (groups I and II) (P  0.05). However, since the whole
repertoire of HLA class I-restricted epitopes for influenza A
virus is not known, it is possible that in HLA-A2-negative
donors a dominant response was elicited against unknown
epitopes. To test whether this was the case or that, indeed, in
HLA-A2-negative donors the CTL response towards influenza
virus is less, the number of influenza A virus-specific CD8
CTL was enumerated in all donors. In Fig. 5A the average
percentage of CTLp frequency is plotted for each of the three
groups. In HLA-A1-, HLA-A2-, HLA-B8-, HLA-B35-positive
donors (group I) 0.28% of the CD8 T cells were influenza A
FIG. 4. Frequency of CTLp specific for individual influenza virus
epitopes. PBMC from HLA-A and -B identical donors were tested for
the frequency of influenza A virus epitope-specific CTLp ex vivo by
using an ELISPOT assay. The graphs represent the different groups of
donors: group I (HLA-A1, -A2, -B8, -B35), group II (HLA-A1, -A2,
-B8, -B27), and group III (HLA-A1, -A3, -B8, -B35). The number of
spots per 2.5  105 PBMC specific for each epitope is given for each
donor individually, and the average number of spots is given for the
entire group (dotted line). The data are given as the average numbers
of specific spots derived from two independent experiments in qua-
druplicate wells, counted by two individuals. Data from donor 8 (HLA-
B*2702) and donors 15 and 16 (HLA-B*3503) were excluded for
NP383–391 and M1128–135, respectively.
FIG. 5. Lower influenza virus-specific CTLp frequencies in HLA-
A2-negative donors. (A) The influenza A virus-specific CTLp fre-
quency (presented as the percentage of virus-specific cells of CD8 T
cells), determined in ELISPOT assay after stimulation with influenza
virus-infected autologous BLCL and with uninfected autologous
BLCL, is plotted for each group of donors: group I (HLA-A1, -A2,
-B8, -B35), group II (HLA-A1, -A2, -B8, -B27), and group III (HLA-
A1, -A3, -B8, -B35). A significant difference (*, P 	 0.028) was found
between CTLp frequency specific for influenza virus in HLA-A2,
-B27 donors (group II) compared to that with HLA-A2-negative
donors (group III). The box comprises the 25th to 75th percentiles,
while the error bars represent the 10th and 90th percentiles from the
average CTLp frequency (solid line). Median CTLp frequency is rep-
resented by a dotted line. (B) Representation of the contribution of
CTLp frequency specific for individual peptides (open bars) to the
total influenza virus-specific CTLp frequency (black bars). The per-
centage of epitope-specific CTLp was calculated for each donor by
dividing the sum of the specific spots found for all epitopes by the
number of CD8 T cells within the PBMC (determined by flow cy-
tometry). Results are given as the average percentages of virus-specific
CTLp frequency (black bars) calculated from 2 to 3 independently
repeated experiments  SD, whereas the epitope-specific CTLp fre-
quency (open bars) was determined in two independently repeated
experiments. Donors 11 and 13 were stimulated with HLA-matched
BLCL from donor 10.
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virus specific, and in HLA-A1-, HLA-A2-, HLA-B8-, HLA-
B27-positive donors (group II) 0.29% were found to be specific
for influenza virus. Donors in group III (HLA-A1, -A3, -B8,
-B35) had a significantly lower (P 	 0.028) influenza virus-
specific CTLp frequency (0.16%) compared to that of group II
(Fig. 5A) but not compared to that of group I (P 	 0.09).
Comparison of all HLA-A2 donors (including donors 17 and
18) with all HLA-A2-negative donors found a significantly
higher frequency of CTLp specific for influenza virus for HLA-
A2 donors (P 	 0.011).
Comparison of the number of spots found after stimulation
with whole virus with that found after stimulation with indi-
vidual peptides revealed that the response against the individ-
ual peptides accounted for 12 to 100% of the total response
against influenza virus (Fig. 5B). Four donors had a response
against the epitopes that was equal to the entire virus-specific
response. Overall a correlation (r 	 0.8; with the exception of
two outliers, donors 3 and 10) was observed between frequen-
cies of virus-specific CTLp and CTL activity (Fig. 6). Figure 6
also shows the difference in CTLp frequency and CTL activity
between HLA-A2-positive and HLA-A2-negative donors.
DISCUSSION
In this study it was shown that there is a relationship be-
tween HLA class I background and the specificity and magni-
tude of the CTL response specific for influenza A virus and its
individual epitopes.
Prior to this study the in vitro stimulation protocol and the
phenotype of the resulting effector cells were validated. It was
concluded that influenza virus-infected PBMC were able to
activate large numbers of cells of a CD8 T-cell clone (A1/NP)
efficiently and quantitatively. In addition, the effector function
was solely mediated by CD8 T cells and the observed CTL
activities were not the result of bystander activation, since the
response to an influenza B virus epitope (NP263–271) was sim-
ilar to the response against uninfected control cells.
The virus used for this study was a reassortant virus of
A/Puerto Rico/8/34 and A/Nanchang/933/95, which contains
the HA, NA, and NP from the A/Nanchang/933/95 virus and all
known CTL epitopes for influenza virus. The donors selected
for this study were between 35 and 50 years of age, thereby
controlling for age-related differences in immune reactivity
and reducing the impact of the number of times the donors had
been infected with influenza virus. All donors had been in-
fected with influenza virus at least once, as indicated by the
presence of virus-specific serum antibodies. Based on the age
of the donors it can be expected, however, that they had been
infected at least two or three times consecutively, which is
important because it has been described that responses against
single epitopes differ between primary and secondary infec-
tions (10, 11).
The number of virus-specific CTLp ex vivo corresponded to
approximately 0.1 to 0.5% of the total number of CD8 T cells,
which is within the normal range of percentages of IFN-
influenza A virus-specific T cells measured by flow cytometry
(unpublished observation). Comparison of the percentage of
virus-specific CTL between groups revealed a significant dif-
ference in CTLp frequency between HLA-A2-positive donors
and HLA-A2-negative donors (Fig. 5 and 6), paralleled by a
lower in vitro CTL activity against influenza virus-infected tar-
get cells in HLA-A2-negative donors. The clinical relevance of
a lower frequency of virus-specific CTLp in individuals infected
with influenza virus and whether a reduced CTLp frequency in
vivo results in a similar reduction in specific CTL activity dur-
ing virus infection remains unknown. This study is not the first
to describe an association between magnitude of CTL response
and HLA phenotype in humans. Disease severity in malaria,
progression to AIDS in HIV-infected individuals, and human
T-cell lymphotropic type I-associated myelopathy were re-
ported to be associated with certain HLA molecules. However,
these findings were mainly based on epidemiological data in
heterogeneous cohorts of donors (20, 26, 30). In contrast, our
study used a very well-defined cohort of HLA identical donors,
enabling us to investigate the relationship between HLA phe-
notype and CTL response in detail.
HLA class I phenotype was found to influence the frequency
of CTLp specific for individual influenza virus epitopes. The
CTLp frequency specific for the HLA-A1-restricted epitope
NP44–52 was significantly higher in HLA-A1-, HLA-A2-, HLA-
B8-, HLA-B35-positive donors (group I) than in both groups II
and III (Fig. 4), resulting in a higher epitope-specific CTL
activity following in vitro stimulation of PBMC with influenza
virus. Since the higher CTLp frequency was observed in group
I and not in groups II and III, it is difficult to link this difference
to one HLA-A or -B molecule. Possibly, HLA-C or HLA class
II molecules have influenced the outcome of the CTL response
to this epitope. It was also noted that the frequency of CTLp
specific for the HLA-B8-restricted epitope NP380–388 was
threefold lower in HLA-B8, B27 donors (group II). This
reduction in frequency of cells specific for the NP380–388 pep-
tide in HLA-B27 donors can be explained by the presentation
of overlapping peptides, as described previously by Tussey et
al. (48). However, after in vitro stimulation with influenza virus
FIG. 6. Correlation between CTL activity and influenza virus-spe-
cific CTLp frequency. Virus-specific CTL activity was plotted, using
influenza virus-infected HLA-matched BLCL at an E:T ratio of 20:1,
against the frequency of virus-specific CTLp (presented as the per-
centage of virus-specific cells of CD8 T cells) obtained from the
ELISPOT assays using influenza virus-infected autologous BLCL. All
18 donors were divided into groups: HLA-A2-negative donors (),
HLA-A2-positive, HLA-B27-negative donors (F), and HLA-A2-posi-
tive, HLA-B27-positive donors (Œ). Two HLA-A2-negative donors (11
and 13) were stimulated with HLA-matched BLCL (donor 10). Donor
8 was excluded from the analysis.
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the difference in CTL activity specific for the NP380–388 epitope
between HLA-B27-positive and HLA-B27-negative donors
was less pronounced.
From the peptide-specific responses it was concluded that
the CTL response against influenza virus is multispecific and
directed against a number of different epitopes. On average,
50% (ranging from 12 to 100%) of the virus-specific response
is accounted for by known viral epitopes, indicating that in
some donors more unknown epitopes are recognized in the
response to influenza virus infections. The variability of the
peptide-specific responses indicates that these data should be
used with caution for the interpretation of the virus-specific
CTL response against all epitopes (9). CTL activity in individ-
ual donors ranged from specificity towards all known peptides
or two peptides, independent of HLA background. The obser-
vation that in humans the influenza virus-specific CTL re-
sponse is directed to multiple epitopes is in agreement with
previously described studies (24, 28).
The dominance of the HLA-A2-restricted epitope M158–66
(24) is less strict than previously thought. Although all donors
had a response to this epitope, 4 out of 11 HLA-A2 donors
showed a greater response against another epitope. In each of
these four cases the dominant epitope was different. This find-
ing adds to a study by Martinon et al., describing a greater
response against an HLA-B37-restricted epitope than the
HLA-A2 epitope M158–66 (35). It was also noted that in several
cases the CTL response restricted to one HLA class I molecule
was directed to both epitopes equally, indicating that there
was no immunodominant response to one of the two epitopes.
A small CTL response to the HLA-B35-restricted epitope
M1128–135 was detected in 2 out of 13 HLA-B35
 donors. A
possible explanation for the low reactivity against this peptide
is the cysteine residue within the epitope enabling the epitope
to form dimers and therefore reduce the ability to bind to the
HLA molecule (14). However, freshly diluted peptide loaded
onto target cells for 1 h did not result in a higher CTL activity.
A second possibility is the relatively low binding affinity of the
epitope to the HLA molecule (19). Finally, the donors selected
for this study can have an undetectable frequency of M1128–135-
specific CTL.
To our knowledge this is the first systematic study in which
influenza virus-specific CTL responses are compared in groups
of donors of well-defined HLA phenotype. The data presented
here indicate that the HLA class I background of individuals
has a major influence on the magnitude and specificity of the
CTL response against influenza A virus. Even in individuals
who share a certain HLA allele, the CTL response restricted by
this HLA allele may be affected by other nonmatching HLA
molecules resulting in different CTL responses. This finding
may have implications on vaccination strategies aiming at the
induction of CD8 T-cell responses.
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